ProCE Banner Activity

How Cabozantinib Is Transforming RCC Clinical Practice

Clinical Thought
Cabozantinib is changing the paradigm in RCC. How should it be integrated into your clinical practice?

Released: December 19, 2016

Expiration: December 18, 2017

No longer available for credit.

Share

Faculty

Won Kim

Won Kim, MD

Assistant Clinical Professor of Medicine and Urology
Genitourinary Medical Oncology Program
University of California, San Francisco
San Francisco, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Exelixis

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Won Kim, MD

Assistant Clinical Professor of Medicine and Urology
Genitourinary Medical Oncology Program
University of California, San Francisco
San Francisco, California

Won Kim, MD, has disclosed that he has received consulting fees from Bayer, Dendreon, and Genentech and has received fund for research support from Novartis.